A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
← catalyst calendarNCT06887348 · readout ≤ 1,595 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
2
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-12 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Metastatic Melanoma
- Advanced Solid Tumor
- Hepatocellular Carcinoma
Intervention
- Other: Observational study with no interventions — also filed as Observational Study
Primary outcomes
what the primary-completion date above is the date OFEvaluate the long-term safety of patients treated with an RPx product
measured Every 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
Identify any delayed adverse event(s) related to treatment with an RPx product
measured Every 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
Identify systemic HSV-1 infection related to treatment with an RPx product
measured Every 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed